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Abstract Aprospective studywasperformedbetween June1996 and December1997, to identifyhowgeneral prac-
titioners (GPs) in Belgium assess asthma severity and how they treat asthma according to their severity assessment.
Threehundred and sixty-¢ve GPsincluded1376 alreadydiagnosed and treated asthmatics.The GPsused aquestionnaire
providing data on patient demographics, aetiology of asthma, symptoms and medication use.The patients provided a
complete diary card of day and night symptoms and morning and evening peak expiratory £ow rates during a 3-week
period.Asthma severityas assessedbyGPswascomparedwiththe severityaccording totheGINAguidelines.Along the
same line, asthma treatment was evaluated according to the GP’s assessment of severity and according to the GINA
guidelines.Confronting the assessment of asthma severity by the GPs with the GINA criteria revealed that about 20%
and 2% of the patients’asthma severity respectively were under-and over-estimated, respectively (using a discrepancy
between GPs and GINA assessmentof severityby 2 ormore classes).Using the GINAcriteria for treatment, only 37?5%
of the patients seemed to be correctly treated.Taking a discrepancy between GINA assessment and treatment of two
classes as an error, 2?3% and 23?4% of the asthmatics are over-and under-treated, respectively. In conclusion, this study
provides evidence that GINA guidelines seem not to be adequately interpreted and implemented by GPs in Belgium.
Improvementof the assessmentof asthma severityis de¢nitelyneeded andmaylead tomore appropriate use of asthma
medication.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1242, available online athttp://www.idealibrary.comon
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Asthma is a chronic in£ammatory disease of the airways
which may cause signi¢cant morbidity and mortality
if not managed optimally. The disease is associated
with a range of symptoms, including cough, particularly
at night, wheeze, di⁄cultybreathing and chest tightness,
which are important in diagnosis of the condition and
assessing its severity. Probably even more important in
the assessment of disease severity are objective mea-
sures of pulmonary function such as peak expiratory
£ow rate (PEFR) and forced expiratory volume in 1sec
(FEV1).
Assessment of disease severity is therefore crucial to
determining optimal treatment. A wide range of di¡er-Received18 June 2001and accepted in revised form10 October 2001.
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E-mail: geert.verleden@uz.kuleuven.ac.beent classes of medication are available for the treatment
of asthma and the selection of the optimal treatment or
combination of agents is essential to ensure that the dis-
ease is well controlled. However, it is unclear how well
the complexities of treatment options are implemented
by physicians routinely managing patients with asthma,
and it has been suggested that the current trends to-
wards increasedmorbidity andmortality associatedwith
asthma may well be due to under-diagnosis and under-
treatment of the disease (1).
In most countries, management of patients with asth-
ma is largely performed by general practitioners (GPs).
This may pose problems because of the complexity of
the disease and the need to constantly monitor a pa-
tient’s condition and adjust treatment if necessary to en-
sure that optimal disease control is achieved. Over the
last decade various sets of guidelines, both national and
international, have been published to assist physicians in
the management of their asthma patients. These guide-
lines, such as those of the Global Initiative for Asthma
ASTHMADRUGUTILIZATIONRESEARCHSTUDY 171(GINA) set out recommended management strategies
according to the severity of disease, prior to any treat-
ment (2). However, it is unclear to what extent these
guidelines are being used in clinical practice and the re-
sults of various previous studies suggest that GPs do
not strictly implement them (3^7). This is of particular
concern since the appropriate management of asthma is
largely dependent on an accurate assessment of severity
and appropriate prescription of medication.The present
study investigated how accurately GPs assess the sever-
ity of disease in their asthma patients andwhether their
prescription ofmedication is appropriate to their assess-
ment of disease severity.
METHODS
This prospective study started recruitment in June1996
and enlisted the last patient in December1997.The study
was approvedby the EthicsCommittee of theUniversity
Hospital Gasthuisberg (Leuven) and oral informed con-
sent was obtained from all participating patients.
A total of 400GPs from Belgiumwere contacted, 356
agreed to participate and were recruited into the study.
The GPswere selected from a list of all practising GPs in
Belgiumbased on a random sample strati¢ed for geogra-
phical area. Each GP taking part in the study was asked
to complete a separate questionnaire for each of ¢ve
consecutive patients with previously diagnosed and al-
ready treated asthma.The questionnaire requested the
following information: (1) assessment of severity of dis-
ease; (2) details of thepatient’s asthma symptoms includ-
ing types of exacerbations and limitation of physical
exercise; (3) overnight PEFR variability; (4) percentage
predicted PEFR, and (5) details of medication prescribed
(Table 1). Each patient included in the study was also
asked to provide the following information: (1) complete
a diary card of symptoms (day and night) for 21days, and
(2) performmorning and evening PEF measurements forTABLE 1. Summaryof questions listed inthe physician’s questionn
K Patientdemographics: age, sex, weight, height, smoker/non-sm
KAsthma aetiology
^ allergic ornon-allergic
^ allergic triggers: pollen, animals, etc
^ other trigger factors: smoke, stress, atmospheric pollution
K Severityof asthma: intermittent, mild, moderate, severe
K Frequencyof symptoms:o1week1,41week1everyday, cont
K Frequencyof nocturnal symptoms:o2 month1, 2^4 month1,
K Types of exacerbations
KNo. of exacerbations in the past12 months
K Patient 24 huse of short-acting bronchodilators: never,o1day
KWhether the patients’physical condition is a¡ectedby their asth
KDetails ofmedicationprescribed
KHistoryof prescriptions21 days. The disease severity of each patient was then
checked by two pulmonologists (G.M.V. and P.D.V.) based
on the criteria speci¢ed in the GINA guidelines (more
speci¢cally day and night symptoms, PEFR (in % pre-
dicted) and PEFR variability, daily medication use).Their
assessments were based on the data provided by the pa-
tients and their GPs.
Details of medication prescribed for each patient was
also recorded in the GP’s questionnaire (Table1). In addi-
tion to recording the class of medication (e.g. inhaled
corticosteroid, short-acting b2-agonist, long-acting b2-
agonist), the overall medication received by each patient
was classi¢ed according to theGINA guidelines into four
categories as detailed inTable 2.
Statistical analyses
Amultivariate analysis was used to assess the diagnostic
parameters that in£uenced the assessmentof asthma se-
verity by the GP. The correlation between diagnostic
parameters and GP assessment of severity was further
assessed by calculation of Spearman’s correlation coe⁄-
cients at a level of statistical signi¢cance of1% (Po0?01).
For data on ordinal scale, statistical tables were pro-
ducedproviding the absolutenumber and thepercentage
per category.
RESULTS
Patients demographics
A total of 1376 patients were included in the survey and
data was obtained from 356 GPs, who thus each re-
cruited on average 3?9 patients into the study.Themean
patient age was 39?2 years (SD, 10?9 years; median, 39?9
years) and the ratio of male: female was approximate1:1
(male, 51?8%; female, 47?6%; gender not recorded, 0?6%).
Almost two-thirds of patients reported not previouslyaire
oker/previous smoker
, physical exercise, infections
inuously
41week1, everynight
1,1^4 day1,44 day1
ma: not at all, a little, somewhat, a lot, extremely
TABLE 2. Classi¢cation of asthmamedicationreceivedbyeachpatient according to GINAcategories
Category Asthma severity Classes ofmedication
Step1 Intermittent Short-acting inhaled b2-agoniston a prnbasis
Step 2 Mildpersistent Short-acting inhaled b2-agonist as
needed + lowdose inhaled
corticosteroid (200^500 mg) or sodium
cromoglycate/nedocromil or theophylline
Step 3 Moderate persistent Short-acting b2-agonist as needed +
mediumdose inhaled
corticosteroid (4500 mg) +
long-acting bronchodilator
(inhaled ororal long-acting
b2-agonistor theophylline)
Step 4 Severe persistent Short-acting b2-agonist as
needed + high dose inhaled
corticosteroid (up to or
4 2000 mg) + long-acting
inhaled b2-agonist and/or
long-acting oral
bronchodilator + oral corticosteroid
172 RESPIRATORYMEDICINEsmoking (60?1%), while 22?7% were current smokers,
13?0% hadpreviously smoked and datawere not available
for 4?2%.Data regarding asthma severity were available
for1324 patients and information on prescribed medica-
tionwas available for1375 patients.
Assessment of disease severity
According to the GP’s assessment of the severity of dis-
ease, 30?5% of patients had intermittent asthma, 29?4%
had mild persistent asthma, 31?4% had moderate persis-
tent asthma and 8?7% had severe asthma.
Analysis of possible correlations between the various
information on disease severity and symptoms supplied
by GPs and their assessment of severity indicated signi-
¢cant correlations (Po0?01according to two-tailed test)
between GP’s perception of disease severity and:
number of symptoms per day, number of symptoms
per night; % predicted PEFR; PEFR variability; in£uence
on physical condition; and type of exacerbation. Values
for Spearman’s correlation coe⁄cient are shown in
Table 3.
A multivariate analysis revealed the GP’s assessment
of disease severity correlated most strongly with
patient’s daytime symptom score, suggesting that this is
the parameter on which GP’s most depend when
assessing disease severity. This is further demonstrated
in Fig. 1 which shows for each class of disease severity
(according to the GP’s assessment), the number of
patients with continuous daytime symptoms, daily
daytime symptoms and less frequent daytime symp-
toms. It seems that for each severity class, most of the
patients in that particular class are classi¢ed correctly.However, a lot of patients are misclassi¢ed, for instance
patients with daily symptoms are also classi¢ed as
intermittent or mild persistent asthmatics. A strong
correlationwas also observedbetween GP’s assessment
and the in£uence of disease on the patient’s physical
condition.
Assessment of disease severity by the pulmonologists
according to the GINA guidelines revealed that respec-
tively16?9% of patients had (while already being treated)
intermittent disease, 17?7% mild persistent disease,
32?6%moderatepersistentdisease and 32?8% severe dis-
ease (Table 4).Thesevalueswere comparedwith theGPs
assessments and patients were regarded as misclassi¢ed
if the discrepancybetween theGP assessment andGINA
assessment was by two or more classes (e.g. GINA as-
sessment of intermittent and GP assessment of moder-
ate or severe, or GINA assessment of severe and GP
assessment of intermittent or mild, etc). Although GPs
correctly estimate disease severity in 78% of patients,
they under-estimate the severity of disease in about
20% of patients, and over-estimate disease severity in
about 2% of patients.When only one GINA class discre-
pancy was used to assess over- or under-estimation of
asthma severity, then, therewas anunder- and over-esti-
mation respectively of asthma severity in about 52% and
12% of the cases, whilst only 36% were classi¢ed
correctly.
Medication use
Information on medication use is shown in Table 5. In-
haled corticosteroids and short-acting b2-agonists were
TABLE 3. Correlation (Spearman’s correlation coe⁄cient) between asthma parameters assessed by GPs and their assessmentof
disease severity
Asthma parameters assessment Spearman’s correlation coe⁄cient (P-value)
Symptoms during the day 0  493 (Po0.01)
Symptoms atnight 0  406 (Po0.01)
% predicted PEFR 0 245 (Po0.01)
Variabilityof PEFR 0 107 (Po0.01)
In£uence of asthma symptoms onphysical condition 0 534 (Po0.01)
Type of exacerbation 0  435 (Po0.01)
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FIG. 1. Correlation between frequency of daytime symptoms and the assessment of severity of disease by the GP. Symptomso1
week1 ( ),1week1^o 1day1 ( ), each day (&), continous (&).
ASTHMADRUGUTILIZATIONRESEARCHSTUDY 173the most frequently prescribed medications, being pre-
scribed to 72?7% and 62?3% of patients respectively.The
other medications prescribed to more than 10% of pa-
tients were short-acting b2-agonist plus anti-cholinergic
(25?9%), long-acting xanthines (23?3%) and sodium cro-
moglycate (10?4%).
Analysis of themedication type according to the clas-
si¢cation criteria described in the GINA guidelines re-
vealed that192 patients (14?5%) were only receiving step
1medication, 752 (56?8%) were receiving step 2 medica-
tion, 272 (20?5%) were receiving step 3 medication and
108 (8?2%) were receiving step 4 medication.These data
were further analysed to determine the disease severity
of patients (as assessed by their GP) in each treatment
group (Table 6). These data revealed that only 37?5%
(497 out of 1324) were correctly treated according to
the GP’s assessment of disease severity and the GINA
guidelines for treatment.This included 24?5% (99 out of404) of patients with intermittent asthma, 64?2% (251
out of 391) of those with mild persistent asthma, 27?2%
(113 outof 416) of thosewithmoderatepersistent asthma
and 30?0% (34 out of113) of thosewith severe persistent
asthma. Slight to signi¢cant under-treatment, therefore,
occurredin 29?6% (392outof1324) patients and a further
32?9% (435 out of1324) were being over-treated, accord-
ing to the GP’s assessment of disease severity.For exam-
ple, 70?0% (79 out of 113) patients with severe asthma
were under-treated, while 75?5% (305 out of 404) pa-
tients with intermittent asthma were probably over-
treated (Table 6).
Analysis of medication use according to disease sever-
ity as assessed by pulmonologists using the GINA guide-
lines also revealed that a signi¢cant number of patients
were being under-treated.When a discrepancy between
GINA assessment and treatment of two classes or great-
er is regarded as an error, 2?3% of patients are over-trea-
TABLE 4. Asthma severity according to GP’s assessment versuspulmonologist’s assessmentusing the GINAguidelines
Pulmonologist (GINA) assessment Total (%)
GPassessment Intermittent Mild Moderate Severe
Intermittent 137 77 120 70 404 (30?5%)
Mild 63 99 156 73 391 (29?4%)
Moderate 21 57 140 98 416 (31?4%)
Severe 2 2 16 93 113 (8?7%)
Total 223 (16?9%) 235 (17?7%) 432 (32?6%) 434 (32?8%) 1324 (100%)
TABLE 5. Prescribedmedications
Asthmamedication Patients receivingmedication, n=1375 (%)
Short-acting b2-agonists 856 (62?3)
Inhaled corticosteroids 1000 (72?7)
Anticholinergics 128 (9?3)
Short-acting b2-agonists plus anticholinergics 356 (25?9)
Sodiumcromoglycate 143 (10?4)
Short-acting xanthines 7 (0?5)
Long-acting xanthines 320 (23?3)
Long-acting b2-agonists (inhaled) 126 (9?2)
Long-acting b2-agonists (oral) 41 (3?0)
Oral steroids 108 (7?9)
Other* 351 (25?5)
*Other include anti-histamines, ketotifen, anti-tussives, etc.
TABLE 6. GPperception of asthma severity versus treatmentcategory according to the GINAguidelines
GPassessment Treatmentcategory according to GINAclassi¢cation Total
Step1 Step 2 Step 3 Step 4
Intermittent 99 (24?5%)* 253 42 10 404 (30?5%)
Mildpersistent 57 251 (64?2%)* 66 17 391 (29?5%)
Moderate persistent 33 223 113 (27?2%)* 47 416 (31?4%)
Severe persistent 3 25 51 34 (30%)* 113 (8?6%)
Total 192 (14?5%) 752 (56?8%) 272 (20?5%) 108 (8?2%) 1324
*The ¢gures in boldrepresentcorrectly treatedpatients.
174 RESPIRATORYMEDICINEted and 23?4% are under-treated.These ¢gures increase
to 19% over-treatment and 54?2% under-treatment if a
discrepancy between assessment and treatment of only
one or more classes is regarded as an error (Table 7).
Under-treatment occurred for instance in 55?3% (240
out of 434) patients with severe asthma and 16?2% (70
out of 432) of patients with moderate asthma (assuming
an error of 2 or more classes between assessment and
treatment).Over-treatment occurred in11?8% (24 out of
223) patients with intermittent asthma and 3?0% (seven
out of 235) of thosewithmild persistent asthma (assum-
ing an error of 2 or more classes between assessment
and treatment). This high level of under-treatment byGPs is in agreement with their signi¢cant under-estima-
tion of the severity of disease (in 29?6% of patients).
DISCUSSION
The results of this study suggest that GPs in Belgium
largely depend on daytime symptoms and the patient’s
physical condition to assess asthma severity, rather than
on all the parameters recommendedby theGINAguide-
lines, although the GINA guidelines were already issued
for a certain time and largely distributed amongst the
GP’s at the time of the study.
TABLE 7. GINA assessmentof severity versus GINAtreatmentclass
Asthma severity:GINAclass Treatmentcategory according to GINAclassi¢cation Total
Step1 Step 2 Step 3 Step 4
Intermittent 51 148 17 7 223 (16?9%)
Mildpersistent 28 152 48 7 235 (17?7%)
Moderate persistent 70 255 83 24 432 (32?6%)
Severe persistent 43 197 124 70 434 (32?8)
Total 192 (14?5%) 752 (56?8%) 272 (20?5%) 108 (8?2%) 1324
ASTHMADRUGUTILIZATIONRESEARCHSTUDY 175Although in our study wehave tried to classify already
treated asthmatics according to theGINAguidelines, we
are perfectly aware that GINA guidelines severity classi-
¢cation applies to symptoms and peak £ow before any
treatment is given. Since most asthmatics are indeed
being treated, it remains, therefore, di⁄cult to assess
the severity of their asthma, when strictly holding on to
theGINAguidelines.Thereforeusing current symptoma-
tology together with PEFR measurements and the need
for medication, may allow to further categorize disease
severity in already treated asthmatics. Such an approach
has previously been used by Liard et al., who demon-
strated an under-estimation of the disease severity in
about 27% of the patients (8).
In our study, itwas also shown thatGPs tend to under-
estimate the severityof the disease (i.e. in approximately
20^52% of patients, according to one or two classes of
discrepancy).The percentage of patients with moderate
to severe asthma, as judged by the two pulmonologists,
seems very high in our study (465%). This is certainly
higher thanwhatwouldbe expected in an asthma popu-
lation. The high percentage might result partly from an
inclusion bias by the GPs. Indeed theymay have included
some of their worst asthmatics, although it had been
asked to include successivepatients.Thebestpossible ex-
planation, however, comes from the fact that the current
medication usewas included to classify patients, and, in-
deed, the study demonstrates that about 33% of the pa-
tients are over-treated, which may categorize them in a
higher disease classi¢cation. As a consequence, this sug-
gests GPs in Belgium do not strictly implement the
guidelines. The reasons for this are not quite clear, but
there are several possibilities, which will be discussed
further.
Possibly as a result of this inadequate assessment
of asthma severity, Belgian GPs tend to under-treat
asthma, when compared to the GINA guidelines. The
present study found that approximately 30% of patients
areprescribedmedication appropriate to less severe dis-
ease than their symptomswouldwarrant, as assessedby
the GP. This is particularly the case for patients with
moderate or severe asthma where 60% and 70% of
patients, respectively, are under-treated.When asthma
severity was assessed according to the GINA guidelines,54% of patients were found to be receiving medication
appropriate to less severe disease.Over-treatment was
also observed in 2^19% of patients (according to either
one or two classes discrepancy that was used). Such dis-
parities between apparent disease severity and pre-
scribed medication, e.g. patients with severe asthma
only receiving b2-agonist relief medication; patientswith
intermittent asthma symptoms receiving systemic ster-
oids, need to be addressed to ensure thatpatients’ symp-
toms arewellmanagedwithout unnecessarymedication
being prescribed.
Our results are in agreement with those from pre-
vious studies in other countries which have revealed
poor implementation of national asthma guidelines. For
example, one study of asthma prescriptions in six British
general practices found that only 58% of patients were
receiving asthma medication regimens that were consis-
tent with those recommended by the British Thoracic
Society 1 year earlier (7). Another U.K. study (4) found
evidence to suggest thatmanagement by GPswith a par-
ticular interest in asthma (members of theGP in Asthma
group) is closer to that recommended by asthma guide-
lines than for other general practitioners. AGreek study
found that only 23% of primary health care physicians in
Greeceprescribed according to asthma guidelines (3). In-
stead, most primary health care physicians in Greece
treat patients according to the recommendations of the
pulmonologist who sees the patient initially. Thus,
changes in asthma severity and response to medication
seem not to be optimally monitored and medication
may not be adjusted accordingly by the GP. AU.S. study
of physicians’ understanding of the National Heart, Lung
and Blood Institute (NHLBI) asthma guidelines found
that themean score achievedby the108 physicians tested
was 60%.Thephysicians testedweremembers of theDi-
vision of Pulmonary, Critical Care, and Occupational
Medicine at the University of Iowa and included 31 asth-
ma specialists. Asthma specialists achieved higher total
scores (mean, 78%) but no groups scored well on esti-
mating disease severity (means scores, 27^56%) (6).This
suggests that improvements in the national asthma
guidelines inmany countriesmaybe appropriate tomake
themmore easily understood and applied in a busy clinic.
As a consequence, one possible explanation for non-
176 RESPIRATORYMEDICINEadherence to the guidelines could be that GPs receive
toomanyguidelines to know them all (GPswith a special
interest in asthma do better) and furthermore that
GINA guidelines are too complex to interpret and that
it may also take too much time from a GP to establish
the real asthma severity based on a thorough interview
of the patient and the search for residual symptoms that
could be tackled with other or add-on medication.This
may explain a great deal of under-treatment.Conversely,
we also have the impression that step-down is rarely
used by GPs. If the patient feels well, the treatment is
considered to be optimal, whichmay explain a great deal
of over-treatment.To resolve this, a standard question-
naire such as the asthma control questionnaire (9) or
the asthma severity score (10) could be used to analyse
the patient’s symptoms/asthma control and the need for
step-up or step-down treatment.
Analysis of overallmedication use in the present study
revealed that approximately 70% of patientswerereceiv-
ing inhaled steroids. This is in agreement with GINA
guidelines and suggests inhaled steroids are, on average,
probablybeingprescribed correctly in Belgium. Similarly
a study of users of asthma medications in Iceland found
that of the patients aged16 years or older, 62%were pre-
scribed inhaled corticosteroids (11). In contrast, a Greek
study found that inhaled corticosteroids constituted
only 24% of asthmamedications (3).However, this repre-
sented a signi¢cant improvement in prescribingpractices
over 3 years in which corticosteroid use increased by
10%, probably in response to better dissemination of
guidelines. In another study performed in the European
Community, only17^49% of thepatientswere on inhaled
anti-in£ammatory drugs. The prevalence of anti-in£am-
matory treatment was, however, positively related to
the prevalence of nocturnal symptoms of asthma (12). In
a recently published studyon asthmamanagement in ¢ve
European countries, the proportion of asthma patients
receiving inhaled steroids varied between 31% in Ger-
many to 58% inThe Netherlands (13). The high percen-
tage of users of inhaled steroids in our study may
represent another bias. Although GPs were asked to in-
clude successive patients with asthma, they may, how-
ever, have preferentially included asthmatics who were
already being treatedwith inhaled steroids.
Although a rather large proportion of our patients
were taking anti-cholinergics, we are fairly convinced
that our patients were indeed asthmatics, based on the
mean age (o40 years), the PEFR and variability, the fact
that over 60% were never-smokers and above all, the
knowledge that using anti-cholinergic agents for asthma
(especially in combination with short-acting b2-agonists
using the same inhaler device), is common practice in
Belgium, although anti-cholinergics are not recom-
mended as relievermedication by GINA.
According to the GINA guidelines, long-acting
bronchodilators (e.g. inhaled/oral long-actingb2-agonistsor oral slow release theophylline) should be used in con-
junction with inhaled corticosteroids in patients with
moderate and severe persistent asthma. In our study ap-
proximately 35% were using these type of drugs, which
still represents anunderusage of this class ofmedication,
which should be used in at least all patients withmoder-
ate or severe asthma, (i.e. approximately 4 40% of all
asthma patients). Especially the use of long-acting in-
haled b2-agonists was very low in our study (9%) and
may well account for a signi¢cant proportion of the ob-
served under-treatment, however, the Belgian reimbur-
sement criteria in use at the time when the study was
performedmay have contributed to this under-use.
More detailed analysis of the patients with severe
asthma receiving oral corticosteroid therapy in our
study, also revealed an under-usage of other therapies in
this class of patients, especially long-acting inhaled or
oralb2-agonists and even inhaled corticosteroids (leuko-
triene receptor antagonists were not yet available at the
time), whichmight again have contributed to suboptimal
management of patients with severe asthma requiring
oral corticosteroid therapy (14).
Assessing asthma severity not only depends on the
questions asked by the physician, but also on the inter-
pretation of the symptomatology by the patients them-
selves.The lattermight also be anothermajor reason for
under-estimation of severity and, hence, under-treat-
ment.This is clearly illustrated in the AIRE study, which
describes the patients asthma insight and the clinical
management of asthma in Europe. It was demonstrated
in this particular study that approximately 50%of thepa-
tients reporting severe persistent asthma symptoms,
considered their asthma to be under control and that
46% of the patients also reported daytime symptoms,
whereas only 23% had taken inhaled steroids over the
past 4 weeks (15).Furthermore, 50% of patients with se-
vere disease perceived their asthma to be well con-
trolled, although their reported quality of life was poor
and their healthcare utilizationwas high (15).
Not only symptom reporting and severity perception
of the patient are important; there still remains thema-
jor problem of non-compliance as a cause of persistent
asthma symptoms. For instance, in an Italian study only
65% of the patients who had received anti-asthma drug
prescriptions declared they had taken all the drugs pre-
scribed (16). And in another recent study from our own
group, the self-reported non-compliance was estimated
as high as 35%, however, varying between 15 and 48%,
depending on the clinical situation of the patients at the
time (17). In the present survey, no attempts were made
to acknowledge the compliance, but it is estimated that
there will have been a high rate of non-compliance since
the study in fact represents real life.
In summary, the results of our study suggest that im-
provements in the assessment of asthma severity in Bel-
gium are warranted (as is also the case in other parts of
ASTHMADRUGUTILIZATIONRESEARCHSTUDY 177the world where this type of study has been done) and
could lead to the more appropriate use of asthmamedi-
cation. In particular, a better understanding of the var-
ious parameters (including rigid assessment of all
possible symptoms (9,10) andpulmonary function criter-
ia,which seem tobe de¢nitelyunder-used (15),which can
be used to assess asthma severity and a better use of
add-on therapies is required. Such improvements in the
understanding of the disease and its treatment (as well
by the physician as by the patient and other healthcare
providers) should ensure that physicians carefully screen
for asthma control, that asthma patients receive the
optimum care they deserve and that they improve
their compliance, which might result in fewer exacerba-
tion episodes (18), hospital admissions and asthma
deaths (19).
Since this studyhasbeenperformedin Belgium (1996^
1997), the local reimbursement criteria for long-acting
inhaled b2-agonists have changed, furthermore, new
guidelines have been published and new therapies have
become available (anti-leukotrienes), therefore, it is
hoped that at the present time, assessing asthma sever-
ity as well as asthma treatment might have improved.
This, however, will have to be demonstrated in a follow-
up study.
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